Method for administering tandospirone

• US 5,858,407 A
• Filed: 01/10/1994
• Issued: 01/12/1999
• Est. Priority Date: 02/27/1992
• Status: Expired due to Term

• Current Assignee: Encinal Pharmaceutical Investments, LLC
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Ridzon, Dana A., Ayer, Atul Devdatt
• Primary Examiner(s): BROUILLETTE, D GABRIELLE
• Application Number:
  US08/179,393
• Time in Patent Office: 1,828 Days
• Field of Search: 424/473
• US Class Current: 424/473
• CPC Class Codes: A61K 31/495 having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazinesA61K31/48 takes precedence ; with three nitrogen atoms A61K31/53
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/505 Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Abstract

A dosage form is provided for administering a drug of the formula ##STR1## to a patient to produce an anxiolytic benefit in the patient. A method is provided for administering the drug of the formula for producing the intended therapy.

Claims

1. A method for treating depression in a patient in need of therapy, wherein the method comprises:

admitting orally into the patient a solid dosage form selected from the group consisting of osmotic, diffusion, bioerosion and ion-exchange comprising 1 mg to 750 mg of a member selected from the group consisting of tandospirone and its pharmaceutically acceptable salts, which member is administered at a dosage controlled-rate of 1 mg to 20 mg per hour over a period of 24 hours by the dosage form to provide antidepressant therapy in the patient.

2. The method for treating depression in a patient according to claim 1, wherein the pharmaceutically acceptable salt is a citrate.

3. A method for treating depressant disorders in a patient in need of antidepressant therapy, wherein the method comprises the step of:

orally admitting into the patient a solid dosage form selected from the group consisting of osmotic, diffusion, bioerosion and ion-exchange comprising 1 mg to 750 mg of tandospirone;

administering the tandospirone to the patient; and

wherein the method is characterized in that the rate of release of 1 mg to 20 mg per hour of tandospirone versus time up to 24 hours is dosage form controlled tandospirone administration to the patient.

4. A method for treating anxiety in a patient in need of anti-anxiety therapy, where the method comprises:

admitting orally a solid dosage form comprising 1 mg to 750 mg of anti-anxiety tandospirone into the patient that is administered at a dosage form controlled rate of 1 mg to 20 mg per hour by a method selected from the group consisting of osmotic, diffusion, bioerosion and ion-exchange over an extended period to provide anti-anxiety tandospirone therapy to the patient.

5. The method for treating anxiety in a patient in need of anti-anxiety therapy, wherein the tandospirone is tandospirone citrate.